You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

BEXSERO: Mechanism of action 1*

BEXSERO was developed, using a multiple antigen approach. Immunization with BEXSERO is intended to raise the titer of bactericidal antibodies that specifically bind the vaccine antigens fHbp, NadA, NHBA and PorA P1.4 (the immunodominant antigen present in the OMV component). 1*

fHbp
Factor H binding protein

NadA
Neisserial adhesin A

NHBA
Neisseria Heparin Binding Antigen

OMV
Outer Membrane Vesicles that contain PorA 1.4

* Clinical significance unknown.

Reference:

  1. BEXSERO Product Monograph. February 25, 2019.

This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit Bexsero.ca.